Rapilysin (reteplase)
- Region
- 🇪🇺 EU
- Active substance
- reteplase
- Company
- Actavis Group PTC ehf
- Status
- Withdrawn
- Therapeutic area
- Myocardial Infarction
- EU approval
- Thu 29 Aug 1996
- Application
- EMEA/H/C/000105
- ATC
- B01AD07
- Official record
- www.ema.europa.eu
Indication
Rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (AMI) symptoms.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Ecokinase Withdrawn · Roche Registration Ltd.
Follow Rapilysin
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.